AbFero Pharmaceuticals Inc. is a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload. Our therapeutic platform addresses transfusional iron overload (TIO) and iron accumulation associated with retinal and neurologic diseases including age-related macular degeneration (AMD), Parkinson’s disease, and traumatic brain injury (TBI). AbFero has completed three clinical trials with the company’s lead iron chelator, SP-420.

Status: Exited, acquired by Pharmacosmos

Announcement Date: September 2020

https://www.abferopharmaceuticals.com

Additional Media Coverage

Pharmacosmos Group Acquires Boston Based Clinical Stage AbFero Pharmaceuticals, Inc.